Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
January 01, 2019
Nature Medicine

UCSF (1) CTD2 researchers identified a synthetic lethal interaction between EGFR tyrosine kinase inhibitors and Aurora kinase inhibitors in acquired resistant cells. This study suggests combinatorial treatment to prevent treatment resistance with the monotherapies.

CTD²
December 26, 2018
Cell Systems

Bioinformatic approach, Similarity Weighted Nonnegative Embedding (SWNE), enables visualization of single-cell gene expression data into biologically relevant factors.

CTD²
December 24, 2018
OncoImmunology

UCSD study suggests that the combination of APOBEC-related mutagenesis and tumor mutation burden may be used as a biomarker of response to immunotherapy.

CTD²
December 21, 2018
Cancers

Analysis of next generation sequencing of patients with hematologic malignancies showed that patients had alterations that could be targeted with gene or immune-targeted therapies.

CTD²
December 21, 2018
Nature Communications

Researchers at DFCI analyzed genome-scale loss-of-function datasets and identified adenosine deaminase acting on RNA as a gene dependency in subsets of lung cancer.

CTD²
December 17, 2018
Cold Spring Harbor Molecular Case Studies

Scientists report that two myeloid leukemia cases with FMS-like tyrosine kinase (FLT3) fusions demonstrate mixed features of myelodysplastic and myeloproliferative syndromes; showed sensitivity to FLT3 inhibitors in ex vivo drug screening assays.

CTD²
December 13, 2018
Cell

CTD2 scientists at Stanford University demonstrated that air-liquid interface patient-derived tumor organoid models retain the original tumor immune cells, enabling testing for personalized immunotherapy in cancer.

CTD²
November 29, 2018
Journal of Molecular Cell Biology

CTD2 researchers at Emory University identify novel role for large tumor suppressor 2, LATS2, as a regulator of the ASK1-mediated stress response pathway which may lead to new strategies to control cellular response to stress in normal cells and diseases.

Pages

CSVXML